Overview

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2025-08-05
Target enrollment:
Participant gender:
Summary
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
Phase:
Phase 1
Details
Lead Sponsor:
Fate Therapeutics
Treatments:
Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Cyclophosphamide
Fludarabine
Immunoglobulins